Wed, July 13, 2022
Tue, July 12, 2022
Mon, July 11, 2022
Sun, July 10, 2022
Fri, July 8, 2022
Thu, July 7, 2022

Marc Goodman Maintained (ACAD) at Buy with Decreased Target to $27 on, Jul 11th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-27-on-jul-11th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Marc Goodman of SVB Leerink, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $31 to $27 on, Jul 11th, 2022.

Marc has made no other calls on ACAD in the last 4 months.



There are 7 other peers that have a rating on ACAD. Out of the 7 peers that are also analyzing ACAD, 2 agree with Marc's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $19 on, Tuesday, June 21st, 2022
  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $27 on, Tuesday, April 19th, 2022


These are the ratings of the 5 analyists that currently disagree with Marc


  • Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Decreased Target to $19 on, Wednesday, June 22nd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, June 21st, 2022
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Increased Target to $31 on, Wednesday, March 16th, 2022

Publication Contributing Sources